Articles

The pro-inflammatory transcription factor is critical for the expression of IL-23, which is known to play a role in psoriasis.

C-Jun Protein Linked to Psoriasis

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Voltaire-X Phase 3 Data for Chronic Plaque Psoriasis Support Interchangeability Application

A study found psoriasis patients treated with biologic therapy had a significant reduction in high-risk plaque in heart arteries over 1 year.

Biologic Therapy for Psoriasis May Reduce Heart Disease

Morgan Petronelli is an associate editor for 

and joined the MJH Life Sciences team in December 2019. She graduated from Youngstown State University in 2019 with a bachelor's degree in journalism and a minor in political science. Prior to graduating, Morgan worked as the editor-in-chief of her college newspaper. She went on to work as an assignment editor at a broadcast news station in Youngstown, Ohio before joining 

She enjoys working out, listening to music, and playing with her dog Scout. You can reach her at 

A new study in Arthritis Care & Research found depression and anxiety reduces the possibility of achieving minimal disease activity in patients with psoriatic arthritis.

Study: Depression, Anxiety Reduce Likelihood of Achieving Minimal Disease Activity in PsA Patients 

New guidance statements related to COVID-19 vaccines and psoriatic disease patients have been published by the National Psoriasis Foundation (NPF) COVID-19 Task Force. 

NPF Issues New Guidance Regarding COVID-19 Vaccines 

Ilya Petrou, MD, is a contributing writer for 

Several systemic therapies are currently available for the treatment of patients with moderate-to-severe psoriasis. Biologics changed the game for treatment. Continued study of and innovation in IL-17 and IL-23 inhibitors promise even better results, but clinicians need to understand each biologic in detail. 

IL-17, IL-23 Inhibitors May Outperform Older Biologics, Oral Therapies

A recent study found patients with high baseline cardiovascular risk who had taken ustekinumab were at increased risk for developing severe cardiovascular events following treatment.

Ustekinumab associated with increased cardiovascular risk in some patients

John Jesitus is a medical writer based in Westminster, CO.

Highlighting the relationship between long-term safety and drug survival, a recent review may help address physician reluctance in prescribing conventional systemic psoriasis treatments. 

Long-term safety and drug survival of oral systemics for psoriasis

In a recent study, psoriasis drugs showed widely variable drug survival rates, owing to differences in safety, efficacy, patient satisfaction and other factors. However, concerns linger over potential to cause long-term cumulative organ toxicity.

Safety profiles differentiate conventional therapies

Comorbidities, co-medication, organ impairment, functional deterioration and frailty make treatment plans challenging for older psoriasis patients. However, these patients should not be precluded but will require more extensive evaluation and assessment, according to a recent study.

Emerging Therapies Plaque Psoriasis